BCL2 and neoplasm: In PLC/PRF/5 tumor‐bearing mice and PDTX mouse models, ZAK‐I‐57 treatment (30 mg/kg) resulted in substantial downregulation of EGFR, c‐Myc, and Bcl‐2, with a concurrent increase in Bax expression (Figures 4F–J and 5G–K).